244 related articles for article (PubMed ID: 35910805)
1. DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis.
Kim JH; Park SY; Jeon SE; Choi JH; Lee CJ; Jang TY; Yun HJ; Lee Y; Kim P; Cho SH; Lee JS; Nam JS
Theranostics; 2022; 12(12):5258-5271. PubMed ID: 35910805
[No Abstract] [Full Text] [Related]
2. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
3. Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.
Wang L; Zhao L; Lin Z; Yu D; Jin M; Zhou P; Ren J; Cheng J; Yang K; Wu G; Zhang T; Zhang D
Clin Transl Med; 2022 May; 12(5):e743. PubMed ID: 35522902
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
[TBL] [Abstract][Full Text] [Related]
5. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
Gao T; Wang M; Xu L; Wen T; Liu J; An G
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
[TBL] [Abstract][Full Text] [Related]
6. Induction of let-7e gene expression attenuates oncogenic phenotype in HCT-116 colorectal cancer cells through targeting of DCLK1 regulation.
Khodadadi Kohlan A; Saidijam M; Amini R; Samadi P; Najafi R
Life Sci; 2019 Jul; 228():221-227. PubMed ID: 31075231
[TBL] [Abstract][Full Text] [Related]
7. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer.
Gzil A; Szylberg Ł; Jaworski D; Dominiak J; Zarębska I; Grzanka D
Anticancer Res; 2019 Jun; 39(6):2689-2697. PubMed ID: 31177103
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer.
Ji D; Zhan T; Li M; Yao Y; Jia J; Yi H; Qiao M; Xia J; Zhang Z; Ding H; Song C; Han Y; Gu J
Stem Cell Reports; 2018 Dec; 11(6):1506-1522. PubMed ID: 30449704
[TBL] [Abstract][Full Text] [Related]
9. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
Kang XL; He LR; Chen YL; Wang SB
World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
[TBL] [Abstract][Full Text] [Related]
10. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer.
Makino S; Takahashi H; Okuzaki D; Miyoshi N; Haraguchi N; Hata T; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y
Carcinogenesis; 2020 May; 41(3):303-312. PubMed ID: 31562741
[TBL] [Abstract][Full Text] [Related]
11. DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer.
Liu W; Wang S; Sun Q; Yang Z; Liu M; Tang H
Int J Cancer; 2018 May; 142(10):2068-2079. PubMed ID: 29277893
[TBL] [Abstract][Full Text] [Related]
12. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
13. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic expression of DCLK1-S, a novel DCLK1 isoform, is associated with tumor aggressiveness and worse disease-specific survival in colorectal cancer.
Kalantari E; Ghods R; Saeednejad Zanjani L; Rahimi M; Eini L; Razmi M; Asadi-Lari M; Madjd Z
Cancer Biomark; 2022; 33(3):277-289. PubMed ID: 34958000
[TBL] [Abstract][Full Text] [Related]
15. Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cells.
Li L; Mei H; Commey ANA
Cancer Gene Ther; 2020 Sep; 27(9):691-701. PubMed ID: 31636360
[TBL] [Abstract][Full Text] [Related]
16. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
17. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition.
Chandrakesan P; Weygant N; May R; Qu D; Chinthalapally HR; Sureban SM; Ali N; Lightfoot SA; Umar S; Houchen CW
Oncotarget; 2014 Oct; 5(19):9269-80. PubMed ID: 25211188
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
[TBL] [Abstract][Full Text] [Related]
19. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.
Ito H; Tanaka S; Akiyama Y; Shimada S; Adikrisna R; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Yamaoka S; Tanabe M
PLoS One; 2016; 11(1):e0146564. PubMed ID: 26764906
[TBL] [Abstract][Full Text] [Related]
20. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
